** Shares of drugmaker Invivyd IVVD.O fall 37.2% to $1.11 premarket

** Co says the U.S. FDA has declined to expand the emergency use authorization of its COVID-19 prevention drug

** The expansion was to include those whose immunity is impaired by certain conditions such as cancer and organ transplant, and for whom alternative options are not accessible or appropriate

** The drug Pemgarda is already authorized for emergency use in those with compromised immunity due to a medical condition or receiving medicines that suppress the immune system, and unlikely to have an adequate response to vaccination

** IVVD fell 88.8% in 2024

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))